EPIC-ATTR: A Study to Evaluate the Effect of Eplontersen on the Transthyretin Reduction and Long-term Safety in Chinese Subjects With Transthyretin Amyloid Cardiomyopathy | oneAMYLOIDOSISvoice
×
recrutement

EPIC-ATTR: A Study to Evaluate the Effect of Eplontersen on the Transthyretin Reduction and Long-term Safety in Chinese Subjects With Transthyretin Amyloid Cardiomyopathy

information clé

numéro d'identification de l'étude : NCT06194825

condition: Cardiomyopathie amyloïde à transthyrétine

statut: Recrutement

objectif:

The purpose of this study is to investigate the effect of eplontersen compared to placebo on the reduction of serum TTR concentration and long-term safety in Chinese participants with hereditary or wild-type transthyretin amyloid cardiomyopathy.

intervention: Eplontersen, Placebo

résultats: https://clinicaltrials.gov/ct2/show/results/NCT06194825

dernière mise à jour: 22 février 2024

détails de l'étude

date de début: 1 décembre 2023

achèvement estimée: 16 mars 2027

dernière mise à jour: 8 janvier 2024

phase de développement : Phase 3

taille / inscription: 60

descriptif de l'étude : This is a Phase 3, randomized study, with initial 24-week double-blind and placebo-controlled treatment phase, then followed by an open-label extension treatment phase to evaluate the effect of eplontersen on the TTR reduction and long-term safety in Chinese participants with ATTR-CM. Eligible participants will be randomized in a 3:1 ratio to either eplontersen or placebo for a treatment period of 24 weeks. The double-blind treatment phase will be followed by 80-week open label treatment phase (Participants initially assigned to placebo will switch to eplontersen treatment at 24 weeks), to evaluate long term safety and tolerability of eplontersen treatment. This study will be performed in about 30 to 35 study centres in China mainland.

résultats principaux :

  • Percent change of serum TTR concentration from baseline
    To evaluate the effect of eplontersen compared to placebo on serum transthyretin (TTR) concentration up to 24 weeks
  • jusqu'à 24 semaines

résultats secondaires :

  • Changes from baseline in NT-proBNP serum level
    jusqu'à 24 semaines
  • Changes from baseline in hs-cTnT serum level
    jusqu'à 24 semaines
  • Plasma concentrations of eplontersen at specified time-points (Week0,2,4,8,12,16,20,24,28,32,36,48,60,72,84,96,104,114,124)
    jusqu'à 124 semaines
  • Plasma concentrations of anti-drug antibodies (ADA) at specified time-points (Week0,2,4,8,12,16,20,24,28,32,36,48,60,72,84,96,104,114,124)
    jusqu'à 124 semaines

Critère d'intégration:

• Âges admissibles : 20 - 90
• Sexes admissibles : tous
Critère d'intégration:

Doit avoir donné son consentement éclairé écrit (signé et daté) et toute autorisation requise par la loi locale et être en mesure de se conformer à toutes les exigences de l'étude.
20 to 90 years of age (inclusive).

Femelles : doivent être non enceintes et non allaitantes et soit :

surgically sterile (e.g., tubal occlusion, hysterectomy, bilateral salpingectomy, bilateral oophorectomy);
post-menopausal (defined as 12 months of spontaneous amenorrhea in females > 55 years of age or, in females ≤ 55 years, 12 months of spontaneous amenorrhea without an alternative medical cause and FSH levels in the post-menopausal range for the laboratory involved);
abstinent* or,
if engaged in sexual relations of child-bearing potential, agree to use 1 highly effective contraceptive method from the time of signing the informed consent form until at least 24 weeks after the last dose of study intervention (eplontersen or placebo).

Males must be surgically sterile or abstinent*; if engaged in sexual relations with a female of child-bearing potential, the participant must be using an acceptable contraceptive method from the time of signing the informed consent form until at least 24 weeks after the last dose of study intervention.

A highly effective method of contraception is defined as one that results in a low failure rate (i.e., less than 1% per year) when used consistently and correctly, such as implants, injectables, hormonal methods etc.

*Abstinence is only acceptable as true abstinence, i.e., when this is in line with the preferred and usual lifestyle of the participant. Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods), declaration of abstinence for the duration of a trial and withdrawal are not acceptable methods of contraception.

Willing to be genetically tested for mutations in the TTR gene before study intervention administration, if it was not done before.
Amyloid deposits in cardiac or non-cardiac tissue confirmed by Congo Red (or equivalent) staining OR technetium scintigraphy (99mTc-3,3-diphosphono-1,2 propanodicarboxylic acid [DPD-Tc], 99m Tc-pyrophosphate [PYP-Tc], or 99mTc-hydroxymethylene-diphosphonate [HMDP-Tc]) with Grade 2 or 3 cardiac uptake in the absence of abnormal light chains ratio, centrally confirmed.
End-diastolic interventricular septum thickness of > 12 mm on screening echocardiogram.

Medical history of HF secondary to hereditary or wild-type ATTR-CM with at least:

prior hospitalization for HF, which may include hospitalization for arrhythmia or pacemaker/implantable cardioverter defibrillator placement, or
symptoms and signs of volume overload or elevated intracardiac pressure that requires treatment with diuretics other than mineralocorticoid receptor antagonists for clinical stabilization.
Screening NT-proBNP ≥ 600 pg/mL(≥ 1200 pg/mL for participants with atrial fibrillation) by central lab.
New York Heart Association (NYHA) class I-III.
6-Minute Walk Distance ≥ 100 meters.
If on medical treatment for HF on stable dosage regimen for at least 2 weeks prior to randomization.
Willing to adhere to vitamin A supplementation per protocol.

critère d'exclusion: Critères:

Les participants sont exclus de l'étude si l'un des critères suivants s'applique :

Acute coronary syndrome, unstable angina, stroke, TIA, coronary revascularization, cardiac device implantation, cardiac valve repair, or major surgery within 3 months prior or during screening.
Hospitalization or urgent visit to emergency department/emergency room for worsening of HF with discharge date within 4 weeks prior to or during screening.
Uncontrolled hypertension (systolic BP > 160 mmHg or diastolic BP > 100 mmHg).
Uncontrolled clinically significant cardiac arrhythmia, per investigator's assessment (e.g., no pacemaker, although indicated).
Severe uncorrected cardiac valvular disease.
Cardiomyopathy not primarily caused by ATTR-CM, for example, cardiomyopathy due to hypertension, valvular heart disease, or ischemic heart disease.

Screening laboratory results as follows, or any other clinically significant abnormalities in screening laboratory values that would render a participant unsuitable for inclusion, per investigator's assessment.

Alanine aminotransferase/aspartate aminotransferase (ALT/AST) > 2.0 × ULN.
Total bilirubin ≥ 2.0 × ULN (participants with total bilirubin ≥ 2.0 × ULN may be allowed on study if indirect bilirubin only is elevated, ALT/AST is not greater than the ULN and known to have Gilbert's disease OR if, in the opinion of the investigator, the bilirubin abnormality is deemed not clinically significant, pending proper follow-up with the local specialist and discussion with Medical Monitor).
Platelets < 125 × 109/L.
Urine protein creatinine ratio (UPCR) ≥ 750 mg/g. In the event of UPCR above this threshold ineligibility may be confirmed by a repeat random spot UPCR UPCR ≥ 750 mg/g.
Positive test for blood (including trace) on urinalysis that is subsequently confirmed with urine microscopy showing > 5 red blood cells per high power field and is related to glomerulopathies. In women, this exclusion criterion must be assessed outside of menstrual period. If in the opinion of the investigator the hematuria is not considered related to glomerulopathies the participant may be considered eligible, pending proper follow-up and a discussion with the Medical Monitor. Participants with history of bladder cancer must have been treated with curative intent and have not presented recurrence within the prior 5 years.
Estimated glomerular filtration rate (eGFR) < 30 mL/min/1.73 m2 at screening (CKD EPI formula [Levey et al. 2009]). If the eGFR is thought to be underestimated, the CKD EPI creatinine-cystatin C equation can be used for confirmation (Inker et al. 2012).
Abnormal thyroid function tests with clinical significance per investigator's judgement.
Serum retinol level at screening < Lower Limit of Normal (LLN) (this criterion does not apply to ATTRv-CM patients with known mutation at the position 84 [e.g., Ile84Ser]).
Hemoglobin A1c (HbA1c) > 9.5%.
Monoclonal gammopathy of undetermined significance (MGUS) and/or alterations in immunoglobulin FLC ratio, unless fat, bone marrow, or heart biopsy confirming the absence of light chain and the presence of TTR protein by mass spectrometry or immunoelectron microscopy. For participants with CKD and without presence of monoclonal protein in blood and urine, the acceptable FLC ratio is 0.26 to 2.25. Results different from that may be discussed with local hematologist, investigator and Medical Monitor if the risks associated with the biopsy outweigh the benefits.
Infection active nécessitant un traitement systémique antiviral ou antimicrobien qui ne sera pas terminé avant le premier jour d'étude.
Known history of or positive test for HIV (as evidenced by positive tests for HIV antibody), hepatitis C (as evidenced by positive tests for HCV antibody and HCV RNA) or hepatitis B (as evidenced by a positive test for hepatitis B surface antigen).
History of bleeding, diathesis or coagulopathy (e.g., liver cirrhosis, hematologic malignancy, antiphospholipid antibody syndrome, congenital disorders such as hemophilia A, B, and Von Willebrand disease).
If receiving oral anticoagulants (except vitamin K antagonists), the dose must have been stable for 4 weeks prior to the first dose of study intervention and regular monitoring must be performed, per clinical practice during the study. If the participant is receiving vitamin K antagonists (e.g., warfarin) INR should be in therapeutic range, as established by the investigator, for 4 weeks prior to the first dose.
Malignancy within 5 years, except for basal or squamous cell carcinoma of the skin, melanoma in situ, prostate carcinoma grade group 1, breast ductal carcinoma in situ, or carcinoma in situ of the cervix. Participants with a history of other malignancies who have been treated with curative intent and without recurrence within 5 years may also be eligible per investigator's judgment.
Prior liver or heart transplant, and/or left ventricular assist device (LVAD) or anticipated liver transplant or LVAD within 1 year after randomization.
Karnofsky performance status of ≤ 50%.
Known Light chain/Primary Amyloidosis.
Known leptomeningeal amyloidosis.
Known history of multiple myeloma.
Treatment with another investigational drug and/or biological agent within 1 month of screening, or 5 half-lives of investigational agent, whichever is longer.
Current or previous treatment with Tegsedi™ (inotersen) or Onpattro™ (patisiran) or other oligonucleotide or RNA therapeutic (including siRNA; does not apply to COVID 19 mRNA vaccinations).
Current treatment with diflunisal, doxycycline with or without ursodeoxycholic acid, and/or non-dihydropyridine calcium-channel blocker (e.g., verapamil, diltiazem). Participants receiving any of these agents must respect a wash-out period of 14 days before randomization.
Unwillingness or inability to comply with study procedures, including follow-up, as specified by this protocol, or unwillingness to cooperate fully with the investigator. For completing PRO assessments, participants who are unable to read (e.g., are blind or are illiterate) should be excluded from participating in this trial.
Other physical, social, or psychological conditions including illicit drug or alcohol use, which, in the opinion of the investigator would make the participant unsuitable for inclusion, or could interfere with the participant participating in or completing the study.

parrainer: AstraZeneca

contacts: Centre d’information sur les études cliniques AstraZeneca, 1-877-240-9479, [email protected]

les enquêteurs: Shuyang Zhang, MD,Peking Union Medical College

emplacements des centres d'essai : Chine

  • Chine
    Site de recherche

  • Chine
    Site de recherche

  • Chine
    Site de recherche

  • Chine
    Site de recherche

  • Chine
    Site de recherche

  • Chine
    Site de recherche

  • Chine
    Site de recherche

  • Chine
    Site de recherche

  • Chine
    Site de recherche

  • Chine
    Site de recherche

  • Chine
    Site de recherche

  • Chine
    Site de recherche

  • Chine
    Site de recherche

  • Chine
    Site de recherche

  • Chine
    Site de recherche

  • Chine
    Site de recherche

  • Chine
    Site de recherche

  • Chine
    Site de recherche

  • Chine
    Site de recherche

  • Chine
    Site de recherche

  • Chine
    Site de recherche

  • Chine
    Site de recherche

  • Chine
    Site de recherche

  • Chine
    Site de recherche

  • Chine
    Site de recherche

  • Chine
    Site de recherche

  • Chine
    Site de recherche

  • Chine
    Site de recherche

  • Chine
    Site de recherche

  • Chine
    Site de recherche

  • Chine
    Site de recherche

  • Chine
    Site de recherche

  • Chine
    Site de recherche

Pour améliorer votre expérience sur ce site, nous utilisons des cookies. Cela inclut les cookies essentiels au fonctionnement de base de notre site Web, les cookies à des fins d'analyse et les cookies nous permettant de personnaliser le contenu du site. En cliquant sur «Accepter» ou sur tout contenu de ce site, vous acceptez que des cookies puissent être placés. Vous pouvez ajuster les paramètres des cookies de votre navigateur en fonction de vos préférences.
Plus d'information

Les paramètres des cookies sur ce site est mis à "accepter les cookies" pour vous donner la meilleure expérience de navigation possible. Si vous continuez à utiliser ce site sans changer vos paramètres de cookies ou vous cliquez sur «Accepter» Consentir ci-dessous et que vous avez à présent.

Fermer

Pour améliorer votre expérience sur ce site, nous utilisons des cookies. Cela inclut les cookies essentiels au fonctionnement de base de notre site Web, les cookies à des fins d'analyse et les cookies nous permettant de personnaliser le contenu du site. En cliquant sur «Accepter» ou sur tout contenu de ce site, vous acceptez que des cookies puissent être placés. Vous pouvez ajuster les paramètres des cookies de votre navigateur en fonction de vos préférences.
Plus d'information

Les paramètres des cookies sur ce site est mis à "accepter les cookies" pour vous donner la meilleure expérience de navigation possible. Si vous continuez à utiliser ce site sans changer vos paramètres de cookies ou vous cliquez sur «Accepter» Consentir ci-dessous et que vous avez à présent.

Fermer